Group 1 - The core product of the company, Tiengogatinib, has completed the first patient dosing in a Phase II clinical study for the treatment of advanced hepatocellular carcinoma in combination with Kangfang Biotech's Ketanib and Idafos. The study aims to evaluate the safety and efficacy of the combination therapy for patients who have not received systemic anti-tumor therapy or have failed standard treatment for advanced liver cancer [1] - The stock price of the company surged over 8%, reaching a new high of 64.8 HKD, which is nearly four times the IPO price of 13.15 HKD. As of the latest update, the stock is trading at 63 HKD with a transaction volume of 11.809 million HKD [1] - The company has been included in the Hang Seng Composite Index, with the changes set to take effect after the market closes on September 5 and will be effective from September 8. This inclusion may lead to adjustments in the eligible stocks for the Hong Kong Stock Connect, as the company meets various criteria including market capitalization, liquidity, and listing duration [1]
港股异动 | 药捷安康-B(02617)涨超8%创新高 替恩戈替尼联用开坦尼/依达方的II期临床试验完成首例患者给药